The impact of external innovation on new drug approvals: A retrospective analysis

• URL: http://arxiv.org/abs/2102.01260v1
• Date: Tue, 2 Feb 2021 02:21:34 GMT
• Title: The impact of external innovation on new drug approvals: A retrospective analysis
• Authors: Xiong Liu, Craig E. Thomas, Christian C. Felder
• Abstract summary: We analyzed the pre-approval publication histories for FDA-approved new molecular entities (NMEs) and new biologic entities (NBEs) launched by 13 top research pharma companies during the last decade (2006-2016) We found that academic institutions contributed the majority of pre-approval publications and that publication subject matter is closely aligned with the strengths of the respective innovator. This may suggest that approved drugs are often associated with a more robust dataset provided by a large number of institutes.
• Score: 0.0
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Pharmaceutical companies are relying more often on external sources of innovation to boost their discovery research productivity. However, more in-depth knowledge about how external innovation may translate to successful product launches is still required in order to better understand how to best leverage the innovation ecosystem. We analyzed the pre-approval publication histories for FDA-approved new molecular entities (NMEs) and new biologic entities (NBEs) launched by 13 top research pharma companies during the last decade (2006-2016). We found that academic institutions contributed the majority of pre-approval publications and that publication subject matter is closely aligned with the strengths of the respective innovator. We found this to also be true for candidate drugs terminated in Phase 3, but the volume of literature on these molecules is substantially less than for approved drugs. This may suggest that approved drugs are often associated with a more robust dataset provided by a large number of institutes. Collectively, the results of our analysis support the hypothesis that a collaborative research innovation environment spanning across academia, industry and government is highly conducive to successful drug approvals.

Related papers

• Two Heads Are Better Than One: A Multi-Agent System Has the Potential to Improve Scientific Idea Generation [48.29699224989952]
  VirSci organizes a team of agents to collaboratively generate, evaluate, and refine research ideas. We show that this multi-agent approach outperforms the state-of-the-art method in producing novel and impactful scientific ideas.
  arXiv  Detail & Related papers  (2024-10-12T07:16:22Z)
• DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning [10.528489471229946]
  We propose a multi-agent framework to enhance the drug repurposing process using state-of-the-art machine learning techniques and knowledge integration. Our framework comprises several specialized agents: an AI Agent trains robust drug-target interaction (DTI) models; a Knowledge Graph Agent utilizes the drug-gene interaction database (DGIdb) to systematically extract DTIs. By integrating outputs from these agents, our system effectively harnesses diverse data sources, including external databases, to propose viable repurposing candidates.
  arXiv  Detail & Related papers  (2024-08-23T21:24:59Z)
• BatGPT-Chem: A Foundation Large Model For Retrosynthesis Prediction [65.93303145891628]
  BatGPT-Chem is a large language model with 15 billion parameters, tailored for enhanced retrosynthesis prediction. Our model captures a broad spectrum of chemical knowledge, enabling precise prediction of reaction conditions. This development empowers chemists to adeptly address novel compounds, potentially expediting the innovation cycle in drug manufacturing and materials science.
  arXiv  Detail & Related papers  (2024-08-19T05:17:40Z)
• Learning a Patent-Informed Biomedical Knowledge Graph Reveals Technological Potential of Drug Repositioning Candidates [6.268435617836703]
  This study presents a novel protocol to analyse various sources such as pharmaceutical patents and biomedical databases. We identify drug repositioning candidates with both technological potential and scientific evidence. Our case study on Alzheimer's disease demonstrates its efficacy and feasibility.
  arXiv  Detail & Related papers  (2023-09-04T02:30:19Z)
• Artificial Intelligence for Drug Discovery: Are We There Yet? [0.08306867559432653]
  Drug discovery is adapting to novel technologies such as data science, informatics, and artificial intelligence (AI) to accelerate effective treatment development. This review discusses the use of AI in the three pillars of drug discovery: diseases, targets, and therapeutic modalities, with a focus on small molecule drugs.
  arXiv  Detail & Related papers  (2023-07-13T01:51:26Z)
• Recent Developments in Structure-Based Virtual Screening Approaches [0.0]
  We give an introduction to the foundations of structure-based virtual screenings. We outline key principles, recent success stories, new methods, available software, and promising future research directions. Virtual screenings have an enormous potential for the development of new small-molecule drugs.
  arXiv  Detail & Related papers  (2022-11-06T19:28:25Z)
• Knowledge-Driven New Drug Recommendation [88.35607943144261]
  We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs. EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base. Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
  arXiv  Detail & Related papers  (2022-10-11T16:07:52Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Discovering Drug-Target Interaction Knowledge from Biomedical Literature [107.98712673387031]
  The Interaction between Drugs and Targets (DTI) in human body plays a crucial role in biomedical science and applications. As millions of papers come out every year in the biomedical domain, automatically discovering DTI knowledge from literature becomes an urgent demand in the industry. We explore the first end-to-end solution for this task by using generative approaches. We regard the DTI triplets as a sequence and use a Transformer-based model to directly generate them without using the detailed annotations of entities and relations.
  arXiv  Detail & Related papers  (2021-09-27T17:00:14Z)
• AI and the future of pharmaceutical research [0.0]
  The paper argues that continued innovation in pharmaceutical AI will enable rapid development of safe and effective therapies for previously untreatable diseases. The industry already reported results such as a 10-fold reduction in drug molecule discovery times. The paper concludes that the focus on pharmaceutical AI put the industry on a trajectory towards another significant disruption: open data sharing and collaboration.
  arXiv  Detail & Related papers  (2021-06-25T17:56:36Z)
• Learning To Navigate The Synthetically Accessible Chemical Space Using Reinforcement Learning [75.95376096628135]
  We propose a novel forward synthesis framework powered by reinforcement learning (RL) for de novo drug design. In this setup, the agent learns to navigate through the immense synthetically accessible chemical space. We describe how the end-to-end training in this study represents an important paradigm in radically expanding the synthesizable chemical space.
  arXiv  Detail & Related papers  (2020-04-26T21:40:03Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.